{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2018"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2274289"],"location":["United States"],"study_start_month":["6"],"keyword":["Metastatic Colorectal Cancer","Cabozantinib","Tumor","Progression Free Survival"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer","description":"This study seeks to use Cabozantinib to treat those with Metastatic Colorectal Cancer who have not previously responded to treatment.","dates":{"creation":"2018-06-15"},"accession":"2274289","cross_references":{"ClinicalTrials___gov":["NCT03542877"]}}